The recent approval in advanced or metastatic HER2/neu-overexpressing GC/GEJ cancer is not limited by patients’ tumor combined positive score (CPS), or microsatellite instability (MSI) or PD-L1 expression. This evidence concerns the gene ERBB2 and neoplasm.